- Home
- HOUS vs GYRE Comparison
HOUS vs GYRE Comparison
Compare HOUS & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOUS
- GYRE
- Stock Information
- Founded
- HOUS 2006
- GYRE 2002
- Country
- HOUS United States
- GYRE United States
- Employees
- HOUS N/A
- GYRE N/A
- Industry
- HOUS Real Estate
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- HOUS Finance
- GYRE Health Care
- Exchange
- HOUS Nasdaq
- GYRE Nasdaq
- Market Cap
- HOUS 1.1B
- GYRE 755.7M
- IPO Year
- HOUS 2006
- GYRE N/A
- Fundamental
- Price
- HOUS $10.12
- GYRE $7.85
- Analyst Decision
- HOUS Hold
- GYRE Strong Buy
- Analyst Count
- HOUS 3
- GYRE 2
- Target Price
- HOUS $8.50
- GYRE $17.00
- AVG Volume (30 Days)
- HOUS 3.4M
- GYRE 81.4K
- Earning Date
- HOUS 11-04-2025
- GYRE 11-12-2025
- Dividend Yield
- HOUS N/A
- GYRE N/A
- EPS Growth
- HOUS N/A
- GYRE N/A
- EPS
- HOUS N/A
- GYRE 0.02
- Revenue
- HOUS $5,783,000,000.00
- GYRE $102,189,000.00
- Revenue This Year
- HOUS $5.89
- GYRE $16.80
- Revenue Next Year
- HOUS $6.45
- GYRE $50.29
- P/E Ratio
- HOUS N/A
- GYRE $461.80
- Revenue Growth
- HOUS 2.74
- GYRE N/A
- 52 Week Low
- HOUS $2.71
- GYRE $6.11
- 52 Week High
- HOUS $12.03
- GYRE $19.00
- Technical
- Relative Strength Index (RSI)
- HOUS 69.39
- GYRE 49.42
- Support Level
- HOUS $9.49
- GYRE $8.17
- Resistance Level
- HOUS $10.34
- GYRE $8.44
- Average True Range (ATR)
- HOUS 0.41
- GYRE 0.41
- MACD
- HOUS -0.11
- GYRE 0.04
- Stochastic Oscillator
- HOUS 61.32
- GYRE 29.60
About HOUS Anywhere Real Estate Inc.
Anywhere Real Estate Inc operates in residential real estate, focusing on brokerage, relocation, title, settlement businesses, and mortgage and title insurance ventures. It supports approximately 1 million home sale sides annually. Brands include Better Homes and Gardens, CENTURY 21, Coldwell Banker, Corcoran, ERA, and Sotheby's International Realty. Revenue comes mainly from existing home transactions. Operations are segmented into Anywhere Brands (franchises), Anywhere Advisors (owned brokerage), and Anywhere Integrated Services (title and settlement).
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.